Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (663)	7/8/2002 10:48:29 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 3561

Regeneron Granted License by Amgen and Immunex to Interleukin-1 Inhibitor Patents TARRYTOWN, N.Y.--(BW HealthWire)--July 8, 2002--Regeneron Pharmaceuticals (Nasdaq: REGN - News) announced that it has entered into an agreement with Amgen Inc. and Immunex Corporation for a non-exclusive license to certain intellectual property rights which may be used in the development and commercialization of Regeneron's Interleukin-1 (IL1) Trap. Amgen and Immunex agreed to grant the license to Regeneron in connection with Amgen's pending acquisition of Immunex, which is currently under review by the Federal Trade Commission. The license to Regeneron becomes effective upon the completion of the acquisition. This license follows two other licensing arrangements under which Regeneron obtained rights to practice intellectual property for potential use in its IL1 Trap program. The Company gained nonexclusive rights to patents owned by ZymoGenetics, Inc. covering immunoglobulin-fusion proteins. In addition, Regeneron has a license from Tularik Inc. for the use of patents covering a receptor accessory protein used in the IL1 Trap. "The IL1 Trap demonstrated clinical activity in patients with rheumatoid arthritis in a Phase I trial, and a Phase II trial is scheduled to begin shortly," noted Stuart Kolinski, Regeneron's Vice President and General Counsel. "We are pleased that at this important time in the compound's development, Regeneron was able to secure these three licenses to intellectual property rights, which enhance our existing patent portfolio for the IL1 Trap, in exchange for total royalties in the mid-single digits."